An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group
Berk M, du Plessis AD, Birkett M, Richardt D
Department of Psychiatry,
University of the Witwatersrand,
Johannesburg, South Africa.
Int Clin Psychopharmacol 1997 May; 12(3):137-40


Duloxetine hydrochloride, a mixed reuptake inhibitor of serotonin and noradrenaline, was studied in a 6 week open-label uncontrolled multicentre design at a dose of 20 mg daily both in in- and outpatients meeting DSM-III-R criteria for unipolar major depressive disorder. Seventy-nine patients took part in the study. The mean score on the 17-item Hamilton Depression Rating Scale at baseline was 24.9 (SD 4.4), decreasing to 8.5 (SD 7.8) after 6 weeks using a last observation carried forward analysis. Clinical response, defined as a 50% reduction in 17-item Hamilton Depression Rating Scale scores, occurred in 78.2% of patients, whereas remission, defined as a 17-item Hamilton Depression Rating Scale score of < or = 6, occurred in 60.3% of patients. Duloxetine hydrochloride was safe and well tolerated in this patient population.
Milnacipran (Ixel)
Venlafaxine (Effexor)
Duloxetine (Cymbalta)
Duloxetine: hope or hype?
Duloxetine for major depression
Duloxetine (Cymbalta): structure
Duloxetine for anxious depressives
Duloxetine (Cymbalta): pharmacology
Duloxetine for pain-ridden depressives
Duloxetine, serotonin and noradrenaline
Duloxetine for stress urinary incontinence
Long-term duloxetine (Cymbalta) for depressives
Duloxetine, a balanced serotonin-noradrenaline reuptake inhibitor

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family